Jerome Zeldis
Director/Board Member at NEXGEL, INC.
Net worth: 582 826 $ as of 29/04/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Robert Farrell | M | 74 | 8 years | |
| Sol Barer | M | 76 |
Semorex, Inc.
Israel Biotech Fund
 Israel Biotech Fund Investment ManagersFinance Israel Biotech Fund (Israel Biotech) is a venture capital firm founded in 2015 by Yuval Cabilly, David Sidransky, and Gidon Zairi. The firm is headquartered in Rehovot, Israel. | 26 years |
| Kenneth Londoner | M | 57 |
Viralclear Pharmaceuticals, Inc.
 Viralclear Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ViralClear Pharmaceuticals, Inc. manufactures anti-viral drug. The company is headquartered in Westport, CT.
Alliqua BioMedical, Inc.
 Alliqua BioMedical, Inc. BiotechnologyHealth Technology Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA. | 9 years |
| Matthew Klein | M | 52 | 5 years | |
| Dorman Followwill | M | 60 | 7 years | |
| Tehila Ben-Moshe | M | - |
Biond Biologics Ltd.
 Biond Biologics Ltd. Pharmaceuticals: MajorHealth Technology Biond Biologics Ltd. engages in drug discovery and development. It offers cell-internalizing antibody platform that will enable antibody-targeting of intra-cellular immune factors. The company was founded by Ori Shilo and Tehila Ben-Moshe and is headquartered in Tel Aviv, Israel. The company was founded by Ori Shilo and Tehila Ben-Moshe and is headquartered in Tel Aviv, Israel. | 8 years |
| Samuel Navarro | M | 68 |
Viralclear Pharmaceuticals, Inc.
Viralclear Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ViralClear Pharmaceuticals, Inc. manufactures anti-viral drug. The company is headquartered in Westport, CT. | 4 years |
| Amir Avniel | M | 50 | 7 years | |
| Adam Levy | M | 61 | 5 years | |
| Christine Utter | F | 46 | 14 years | |
| Yuval Cabilly | M | 44 |
Biond Biologics Ltd.
Biond Biologics Ltd. Pharmaceuticals: MajorHealth Technology Biond Biologics Ltd. engages in drug discovery and development. It offers cell-internalizing antibody platform that will enable antibody-targeting of intra-cellular immune factors. The company was founded by Ori Shilo and Tehila Ben-Moshe and is headquartered in Tel Aviv, Israel. The company was founded by Ori Shilo and Tehila Ben-Moshe and is headquartered in Tel Aviv, Israel.
Israel Biotech Fund
Israel Biotech Fund Investment ManagersFinance Israel Biotech Fund (Israel Biotech) is a venture capital firm founded in 2015 by Yuval Cabilly, David Sidransky, and Gidon Zairi. The firm is headquartered in Rehovot, Israel. | 10 years |
| Alexis Nahama | M | - | 7 years | |
| Allan Jacobson | M | 78 | 26 years | |
| Steven Glassman | M | 59 | 3 years | |
| Jonathan Guarino | M | 51 | 5 years | |
| Maghsoud Dariani | M | - |
Semorex, Inc.
| - |
| Victoria Rudman | F | 56 | 9 years | |
| Ann D. Kwong | M | - |
Trek Therapeutics PBC
 Trek Therapeutics PBC Pharmaceuticals: MajorHealth Technology Trek Therapeutics PBC is a for-profit company based in Cambridge, MA. The private company's mission is to develop medicines to treat infectious diseases and make them available to populations in need. The founders of the company, Jerome B. Zeldis and Ann D. Kwong, have collectively participated in developing seven approved antiviral drugs. The company aims to profitably develop safe, novel medicines for infectious diseases at affordable prices. Ann D. Kwong has been the CEO since incorporation. | - |
| Keith Brownlie | M | 71 |
Trek Therapeutics PBC
Trek Therapeutics PBC Pharmaceuticals: MajorHealth Technology Trek Therapeutics PBC is a for-profit company based in Cambridge, MA. The private company's mission is to develop medicines to treat infectious diseases and make them available to populations in need. The founders of the company, Jerome B. Zeldis and Ann D. Kwong, have collectively participated in developing seven approved antiviral drugs. The company aims to profitably develop safe, novel medicines for infectious diseases at affordable prices. Ann D. Kwong has been the CEO since incorporation. | 10 years |
| Ori Shilo | M | 58 |
Biond Biologics Ltd.
Biond Biologics Ltd. Pharmaceuticals: MajorHealth Technology Biond Biologics Ltd. engages in drug discovery and development. It offers cell-internalizing antibody platform that will enable antibody-targeting of intra-cellular immune factors. The company was founded by Ori Shilo and Tehila Ben-Moshe and is headquartered in Tel Aviv, Israel. The company was founded by Ori Shilo and Tehila Ben-Moshe and is headquartered in Tel Aviv, Israel. | 8 years |
| Steinberg Sarit | F | - |
Israel Biotech Fund
Israel Biotech Fund Investment ManagersFinance Israel Biotech Fund (Israel Biotech) is a venture capital firm founded in 2015 by Yuval Cabilly, David Sidransky, and Gidon Zairi. The firm is headquartered in Rehovot, Israel. | 9 years |
| Christopher Schaber | M | 57 | 18 years | |
| Neil Almstead | M | 57 | 24 years | |
| Gilla Kaplan | M | 76 |
Israel Biotech Fund
Israel Biotech Fund Investment ManagersFinance Israel Biotech Fund (Israel Biotech) is a venture capital firm founded in 2015 by Yuval Cabilly, David Sidransky, and Gidon Zairi. The firm is headquartered in Rehovot, Israel. | 21 years |
| Anthony Zook | M | 63 |
Viralclear Pharmaceuticals, Inc.
Viralclear Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ViralClear Pharmaceuticals, Inc. manufactures anti-viral drug. The company is headquartered in Westport, CT. | 4 years |
| David Sidransky | M | 64 |
Biond Biologics Ltd.
Biond Biologics Ltd. Pharmaceuticals: MajorHealth Technology Biond Biologics Ltd. engages in drug discovery and development. It offers cell-internalizing antibody platform that will enable antibody-targeting of intra-cellular immune factors. The company was founded by Ori Shilo and Tehila Ben-Moshe and is headquartered in Tel Aviv, Israel. The company was founded by Ori Shilo and Tehila Ben-Moshe and is headquartered in Tel Aviv, Israel.
Israel Biotech Fund
Israel Biotech Fund Investment ManagersFinance Israel Biotech Fund (Israel Biotech) is a venture capital firm founded in 2015 by Yuval Cabilly, David Sidransky, and Gidon Zairi. The firm is headquartered in Rehovot, Israel. | 10 years |
| Michael Schmertzler | M | 72 | 23 years | |
| Joseph S. Camardo | M | 69 |
Mali Health Organizing Project
| 11 years |
| Mark Boulding | M | 63 | 22 years | |
| David Southwell | M | 63 | 19 years | |
| Diane Parks | F | 71 | 5 years | |
| Mary Smith | F | 61 | 3 years | |
| Robert Rubin | M | 78 | 15 years | |
| Stephanie Okey | F | 64 | 6 years | |
| Ellen Welch | M | - | - | |
| Michael Bator | M | 60 |
Trek Therapeutics PBC
Trek Therapeutics PBC Pharmaceuticals: MajorHealth Technology Trek Therapeutics PBC is a for-profit company based in Cambridge, MA. The private company's mission is to develop medicines to treat infectious diseases and make them available to populations in need. The founders of the company, Jerome B. Zeldis and Ann D. Kwong, have collectively participated in developing seven approved antiviral drugs. The company aims to profitably develop safe, novel medicines for infectious diseases at affordable prices. Ann D. Kwong has been the CEO since incorporation.
Israel Biotech Fund
Israel Biotech Fund Investment ManagersFinance Israel Biotech Fund (Israel Biotech) is a venture capital firm founded in 2015 by Yuval Cabilly, David Sidransky, and Gidon Zairi. The firm is headquartered in Rehovot, Israel. | 2 years |
| Gregg Lapointe | M | 65 | 15 years | |
| Gertjan Bartlema | M | - |
Immodulon Therapeutics Ltd.
 Immodulon Therapeutics Ltd. BiotechnologyHealth Technology Part of Lifexx SA, Immodulon Therapeutics Ltd. is a late-stage clinical biotechnology company based in Uxbridge, UK. Immodulon is developing a highly differentiated cancer immunotherapy approach that primes the patient’s own innate immune system with the aim to significantly enhance the efficacy of a broad range of anti-cancer therapies, including chemotherapy and checkpoint inhibitors. The British company is developing imm-101, a heat-killed mycobacterium obuense, as a broad-spectrum immunomodulatory agent with the potential to treat a range of difficult-to-treat tumors including those considered to be immunologically “ cold, ” such as pancreatic cancer. Immodulon's imm-101 based immunotherapy complements other cancer therapies, including immune checkpoint inhibitors and chemotherapy. The private company is focused on developing safe and effective immunotherapy treatments. The company was founded in 2007 by Charles Akle, John L. Stanford. Gertjan Bartlema has been the CEO of the company since 2022. | 2 years |
| Morris Priwler | M | - |
Semorex, Inc.
| - |
| Jeffrey O'Donnell | M | 64 |
Viralclear Pharmaceuticals, Inc.
Viralclear Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ViralClear Pharmaceuticals, Inc. manufactures anti-viral drug. The company is headquartered in Westport, CT. | 2 years |
| David Lemus | M | 61 | 7 years | |
| Scott Henry | M | 53 | 1 years | |
| Glenn Steele | M | 79 | 9 years | |
| Paul Billings | M | 71 | 7 years | |
| Emma Reeve | F | 63 | 6 years | |
| Nicholas U. Spring | M | - |
Viralclear Pharmaceuticals, Inc.
Viralclear Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ViralClear Pharmaceuticals, Inc. manufactures anti-viral drug. The company is headquartered in Westport, CT. | - |
| Martin Rexroad | M | - | 11 years | |
| Robert Spiegel | M | 73 |
Israel Biotech Fund
Israel Biotech Fund Investment ManagersFinance Israel Biotech Fund (Israel Biotech) is a venture capital firm founded in 2015 by Yuval Cabilly, David Sidransky, and Gidon Zairi. The firm is headquartered in Rehovot, Israel. | 13 years |
| Gidon Zairi | M | - |
Israel Biotech Fund
Israel Biotech Fund Investment ManagersFinance Israel Biotech Fund (Israel Biotech) is a venture capital firm founded in 2015 by Yuval Cabilly, David Sidransky, and Gidon Zairi. The firm is headquartered in Rehovot, Israel. | 10 years |
| Grant Verstandig | M | 34 | 3 years | |
| Nachum Stein | M | 75 | 5 years | |
| Steven Lisi | M | 53 | 7 years | |
| Alethia Young | F | 45 | 2 years | |
| Richard Brudnick | M | 67 |
Israel Biotech Fund
Israel Biotech Fund Investment ManagersFinance Israel Biotech Fund (Israel Biotech) is a venture capital firm founded in 2015 by Yuval Cabilly, David Sidransky, and Gidon Zairi. The firm is headquartered in Rehovot, Israel. | 6 years |
| Murad Husain | M | - | 10 years | |
| Stan Bernard | M | - |
Israel Biotech Fund
Israel Biotech Fund Investment ManagersFinance Israel Biotech Fund (Israel Biotech) is a venture capital firm founded in 2015 by Yuval Cabilly, David Sidransky, and Gidon Zairi. The firm is headquartered in Rehovot, Israel. | - |
| Charles M. Rice | M | - |
Trek Therapeutics PBC
Trek Therapeutics PBC Pharmaceuticals: MajorHealth Technology Trek Therapeutics PBC is a for-profit company based in Cambridge, MA. The private company's mission is to develop medicines to treat infectious diseases and make them available to populations in need. The founders of the company, Jerome B. Zeldis and Ann D. Kwong, have collectively participated in developing seven approved antiviral drugs. The company aims to profitably develop safe, novel medicines for infectious diseases at affordable prices. Ann D. Kwong has been the CEO since incorporation. | - |
| Murray McKinnell | M | - |
Trek Therapeutics PBC
Trek Therapeutics PBC Pharmaceuticals: MajorHealth Technology Trek Therapeutics PBC is a for-profit company based in Cambridge, MA. The private company's mission is to develop medicines to treat infectious diseases and make them available to populations in need. The founders of the company, Jerome B. Zeldis and Ann D. Kwong, have collectively participated in developing seven approved antiviral drugs. The company aims to profitably develop safe, novel medicines for infectious diseases at affordable prices. Ann D. Kwong has been the CEO since incorporation. | - |
| Kylie O'Keefe | F | - | 6 years | |
| Jeffrey Berkowitz | M | 58 |
Israel Biotech Fund
Israel Biotech Fund Investment ManagersFinance Israel Biotech Fund (Israel Biotech) is a venture capital firm founded in 2015 by Yuval Cabilly, David Sidransky, and Gidon Zairi. The firm is headquartered in Rehovot, Israel. | - |
| George Demetri | M | 67 |
Harvard Medical School
| 36 years |
| Murray Goldberg | M | 79 |
Israel Biotech Fund
Israel Biotech Fund Investment ManagersFinance Israel Biotech Fund (Israel Biotech) is a venture capital firm founded in 2015 by Yuval Cabilly, David Sidransky, and Gidon Zairi. The firm is headquartered in Rehovot, Israel. | - |
| Arnold Levine | M | 84 |
Robert Wood Johnson Medical School
| 21 years |
| Edward Saltzman | M | 69 |
Israel Biotech Fund
Israel Biotech Fund Investment ManagersFinance Israel Biotech Fund (Israel Biotech) is a venture capital firm founded in 2015 by Yuval Cabilly, David Sidransky, and Gidon Zairi. The firm is headquartered in Rehovot, Israel. | 9 years |
| Joshua Barer | M | - |
Israel Biotech Fund
Israel Biotech Fund Investment ManagersFinance Israel Biotech Fund (Israel Biotech) is a venture capital firm founded in 2015 by Yuval Cabilly, David Sidransky, and Gidon Zairi. The firm is headquartered in Rehovot, Israel. | 9 years |
| Ariel Kamsler | M | - |
Israel Biotech Fund
Israel Biotech Fund Investment ManagersFinance Israel Biotech Fund (Israel Biotech) is a venture capital firm founded in 2015 by Yuval Cabilly, David Sidransky, and Gidon Zairi. The firm is headquartered in Rehovot, Israel. | 7 years |
| Michael W. Smith | M | - |
PTC Corp.
| - |
| Pierre Gravier | M | 39 | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Mark Alles | M | 64 | 15 years | |
| Dave Stefansky | M | 52 |
Alliqua BioMedical, Inc.
Alliqua BioMedical, Inc. BiotechnologyHealth Technology Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA. | 9 years |
| Jason Lane | M | 52 | 2 years | |
| Scott Carmer | M | 59 | 8 years | |
| Brian Posner | M | 62 |
Alliqua BioMedical, Inc.
Alliqua BioMedical, Inc. BiotechnologyHealth Technology Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA. | 5 years |
| Steven C. Berger | M | 63 |
Alliqua BioMedical, Inc.
Alliqua BioMedical, Inc. BiotechnologyHealth Technology Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA. | 3 years |
| Robert Hugin | M | 69 | 19 years | |
| Jacqualyn Fouse | M | 62 | 7 years | |
| Evan Myrianthopoulos | M | 59 | 10 years | |
| Jonathan Biller | M | 61 | 8 years | |
| David Ian Johnson | M | 66 |
Alliqua BioMedical, Inc.
Alliqua BioMedical, Inc. BiotechnologyHealth Technology Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA. | - |
| Robert Knight | M | 73 | 19 years | |
| Perry Karsen | M | 69 |
Alliqua BioMedical, Inc.
Alliqua BioMedical, Inc. BiotechnologyHealth Technology Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA. | 12 years |
| Thomas Daniel | M | 69 | 10 years | |
| Scott Smith | M | 61 | 10 years | |
| Karen R. Krumeich | F | 70 | 3 years | |
| Peter Kellogg | M | 67 | 5 years | |
| Richard Berman | M | 81 | 3 years | |
| Stuart Peltz | M | 64 | 25 years | |
| Johan Spoor | M | 52 | 4 years | |
| Douglas J. Langston | M | 63 | 3 years | |
| Ronald Erickson | M | 80 | 6 years | |
| Marcio Souza | M | 45 | 6 years | |
| Cellia Habita | M | - |
Immodulon Therapeutics Ltd.
Immodulon Therapeutics Ltd. BiotechnologyHealth Technology Part of Lifexx SA, Immodulon Therapeutics Ltd. is a late-stage clinical biotechnology company based in Uxbridge, UK. Immodulon is developing a highly differentiated cancer immunotherapy approach that primes the patient’s own innate immune system with the aim to significantly enhance the efficacy of a broad range of anti-cancer therapies, including chemotherapy and checkpoint inhibitors. The British company is developing imm-101, a heat-killed mycobacterium obuense, as a broad-spectrum immunomodulatory agent with the potential to treat a range of difficult-to-treat tumors including those considered to be immunologically “ cold, ” such as pancreatic cancer. Immodulon's imm-101 based immunotherapy complements other cancer therapies, including immune checkpoint inhibitors and chemotherapy. The private company is focused on developing safe and effective immunotherapy treatments. The company was founded in 2007 by Charles Akle, John L. Stanford. Gertjan Bartlema has been the CEO of the company since 2022. | - |
| Miranda Toledano | F | 47 | 5 years | |
| Timothy J. Smith | M | - | - | |
| Michael L. Kranda | M | 69 | 12 years | |
| Soren Keller | M | - |
Bionor Pharma ASA
 Bionor Pharma ASA Pharmaceuticals: OtherHealth Technology Bionor Pharma ASA engages in research and development, patenting, and commercialization of products in the pharmaceuticals and biotech industry. The company focuses on the research and development of peptide-based vaccines against viral diseases, primarily HIV. The company was founded on January 2, 1993 and is headquartered in Oslo, Norway. | - |
| Kurt J. W. Andrews | M | 54 | 9 years | |
| Emily Hill | F | 44 | - | |
| Robert Hershberg | M | 61 | 5 years | |
| Cláudia Hirawat | F | 53 | 15 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 84 | 84.00% |
| Israel | 17 | 17.00% |
| United Kingdom | 2 | 2.00% |
| Norway | 1 | 1.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Jerome Zeldis
- Personal Network
